Literature DB >> 11151803

Reactive oxygen species and nitric oxide in myocardial ischemia and reperfusion.

B F Becker1, C Kupatt, P Massoudy, S Zahler.   

Abstract

Oxygen radicals and reactive oxygen species (ROS) are known to be generated in large amounts under inflammatory conditions and in the first few minutes of postischemic organ reperfusion. Due to the interaction of ROS with nitric oxide (NO), formed constitutively by endothelial cells, two alternatives are feasible. On the one hand, reaction with superoxide radicals may induce toxification (formation of peroxynitrite), and, on the other hand, by reacting with superoxide and hydroxyl radicals, NO can serve as a radical scavenger (formation of the innocuous anions, nitrate and nitrite, respectively). However, NO is considered to play a pivotal role in numerous physiological and pathophysiological processes, with effects arising from both lack and surfeit of this easily diffusible and chemically very reactive molecule. Physiologic contributions to vascular dilatation and inhibition of platelet and leukocyte activation, e.g., are infringed by enhanced inactivation of NO. Such inactivation occurs readily due to spontaneous reaction of NO with the superoxide radical, formed, e.g., by stressed endothelial cells and activated leukocytes. Conversely, overproduction of NO by induced NO synthase (iNOS) may lead to circulatory shock, cell apoptosis or even cell necrosis. Caution would, thus, seem to be warranted when attempting to interfere with homeostasis of NO. We have investigated the ability of NO to act as a radical scavenger during myocardial reperfusion in experimental and clinical settings. In the former, inhibition of angiotensin converting enzyme was employed to generate more endogenous NO (via bradykinin), in the latter, low-dose sodium nitroprusside was used as the donor of exogenous NO in patients undergoing coronary bypass grafting. Inhibition of leukocyte adhesion, attenuation of platelet activation and mitigation of redox-stress and inflammation were observed in both instances. Accordingly, modest enhancement of NO levels should afford cardioprotection during reperfusion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11151803     DOI: 10.1007/s003920070037

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  7 in total

1.  Brain oxygen and metabolism during circulatory arrest with intermittent brief periods of low-flow cardiopulmonary bypass in newborn piglets.

Authors:  Steven Schultz; Diego Antoni; Gregory Shears; Scott Markowitz; Peter Pastuszko; William Greeley; David F Wilson; Anna Pastuszko
Journal:  J Thorac Cardiovasc Surg       Date:  2006-10       Impact factor: 5.209

2.  The use of diagnostic frequency continuous ultrasound to improve microcirculatory function after ischemia-reperfusion injury.

Authors:  C Makena Hightower; Marcos Intaglietta
Journal:  Microcirculation       Date:  2007-08       Impact factor: 2.628

3.  Vitamin C pretreatment attenuates hypoxia-induced disturbance of sodium currents in guinea pig ventricular myocytes.

Authors:  Hao Zhou; Ji-Hua Ma; Pei-Hua Zhang; An-Tao Luo
Journal:  J Membr Biol       Date:  2006-10-14       Impact factor: 1.843

4.  Early iNOS impairment and late eNOS enhancement during reperfusion following 2.49 MHz continuous ultrasound exposure after ischemia.

Authors:  C Makena Hightower; Marcos Intaglietta
Journal:  Ultrason Sonochem       Date:  2008-05-24       Impact factor: 7.491

Review 5.  The role of mast cells in ischemia and reperfusion injury.

Authors:  Mu-qing Yang; Yuan-yuan Ma; Jing Ding; Ji-yu Li
Journal:  Inflamm Res       Date:  2014-08-10       Impact factor: 4.575

Review 6.  Vascular changes after cardiac surgery: role of NOS, COX, kinases, and growth factors.

Authors:  Neel R Sodha; Richard T Clements; Frank W Sellke
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

Review 7.  Mast Cell: A Multi-Functional Master Cell.

Authors:  Melissa Krystel-Whittemore; Kottarappat N Dileepan; John G Wood
Journal:  Front Immunol       Date:  2016-01-06       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.